DK2552943T3 - Effektiv fremstilling af rekombinante autonome parvovira ved brug af en fra adenovirus afledt hjælper-vektor - Google Patents

Effektiv fremstilling af rekombinante autonome parvovira ved brug af en fra adenovirus afledt hjælper-vektor Download PDF

Info

Publication number
DK2552943T3
DK2552943T3 DK11716475.6T DK11716475T DK2552943T3 DK 2552943 T3 DK2552943 T3 DK 2552943T3 DK 11716475 T DK11716475 T DK 11716475T DK 2552943 T3 DK2552943 T3 DK 2552943T3
Authority
DK
Denmark
Prior art keywords
recombinant
parvovirus
cells
virus
production
Prior art date
Application number
DK11716475.6T
Other languages
English (en)
Inventor
Jean Rommelaere
Max Endele
Nazim El-Andaloussi
Antonio Marchini
Barbara Leuchs
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK2552943T3 publication Critical patent/DK2552943T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14341—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14341—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C12N2750/14352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (6)

1. Fremgangsmåde til fremstilling af en rekombinant autonom parvovirus kendetegnet ved, at 5 (i) HEK 293T-celler undergår transfektion med (a) en rekombinant parvovirus-vektor afledt fra rotte-parvovirus H-1 (H-1) eller muse-minute-virus (MVM), idet der mangler Kapsid-virus- 10 proteinets VP1- og VP2-gener, men hvor der er bevaret det ikke-strukturelle proteins NSl/2-kodende sekvenser, (b) en vektor, som indeholder generne, der koder parvovirus-VPl- og -VP2-Kapsid-proteiner, og (c) en fra adenovirus afledt hjælper-vektor omfattende de adenovirale Ad5 15 DNA-sekvenser fra E2a-genet, E4(orf6)-genet og et VAI RNA-gen; og (ii) den rekombinante parvovirus, som mangler VP1- og VP2-generne, men bevarer de NSl/2-kodende sekvenser, efter celledyrkningen befinder sig isoleret fra HEK 293T-celleme eller mediet. 20
2. Fremgangsmåde ifølge krav 1, hvor i den rekombinante parvovirus-vektor VP1- og VP2-geneme er erstattet af et transgen.
3. Fremgangsmåde ifølge krav 2, hvor expressionen af transgenet står under kontrol af 25 P38-promoteren.
4. Fremgangsmåde ifølge krav 2 eller 3, hvor transgenet er et gen, som koder et markør-protein.
5. Fremgangsmåde ifølge krav 2 eller 3, hvor transgenet er et gen, som koder en tera peutisk eller immunogenisk polypeptid.
6. Fremgangsmåde ifølge krav 5, hvor det terapeutiske protein er en cytotoksisk polypeptid, cytokin og/eller chemokin. 35
DK11716475.6T 2010-03-26 2011-03-24 Effektiv fremstilling af rekombinante autonome parvovira ved brug af en fra adenovirus afledt hjælper-vektor DK2552943T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10003296.0A EP2368903B1 (en) 2010-03-26 2010-03-26 Adenovirus derived helper virus for enhancing recombinant parvovirus production
PCT/EP2011/001493 WO2011116974A2 (en) 2010-03-26 2011-03-24 Adenovirus derived helper virus for enhancing recombinant parvovirus production

Publications (1)

Publication Number Publication Date
DK2552943T3 true DK2552943T3 (da) 2018-08-13

Family

ID=42537981

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10003296.0T DK2368903T3 (da) 2010-03-26 2010-03-26 Adenovirusafledt hjælpevirus til fremme af produktion af rekombinant parvovirus
DK11716475.6T DK2552943T3 (da) 2010-03-26 2011-03-24 Effektiv fremstilling af rekombinante autonome parvovira ved brug af en fra adenovirus afledt hjælper-vektor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10003296.0T DK2368903T3 (da) 2010-03-26 2010-03-26 Adenovirusafledt hjælpevirus til fremme af produktion af rekombinant parvovirus

Country Status (8)

Country Link
US (1) US9803219B2 (da)
EP (2) EP2368903B1 (da)
JP (1) JP5829265B2 (da)
AU (1) AU2011231998B2 (da)
CA (1) CA2794383C (da)
DK (2) DK2368903T3 (da)
ES (2) ES2461147T3 (da)
WO (1) WO2011116974A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2461147T3 (es) * 2010-03-26 2014-05-16 Deutsches Krebsforschungszentrum Virus cooperador obtenido a partir de adenovirus para mejorar la producción de parvovirus recombinantes
EP2620503B1 (en) * 2012-01-27 2014-10-22 Deutsches Krebsforschungszentrum Modified parvovirus useful for gene silencing
EP3327124A1 (en) * 2016-11-28 2018-05-30 Deutsches Krebsforschungszentrum H-1 pv expressing rnai effectors targeting cdk9
EP3754015A1 (en) * 2019-06-17 2020-12-23 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Optimized parvovirus h-1 production
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
WO2022250491A1 (en) * 2021-05-27 2022-12-01 Neuracle Genetics Inc. Novel dual helper plasmid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
ATE329046T1 (de) * 1998-10-14 2006-06-15 Deutsches Krebsforsch Parvovirus-vektoren und deren verwendung
JP2003511037A (ja) * 1999-10-01 2003-03-25 ジェノボ， インコーポレイテッド ＡＡＶｒｅｐ／ｃａｐ遺伝子を含むアデノウイルスを使用する組換えＡＡＶの産生
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
ES2461147T3 (es) * 2010-03-26 2014-05-16 Deutsches Krebsforschungszentrum Virus cooperador obtenido a partir de adenovirus para mejorar la producción de parvovirus recombinantes

Also Published As

Publication number Publication date
JP5829265B2 (ja) 2015-12-09
ES2683002T3 (es) 2018-09-24
JP2013539957A (ja) 2013-10-31
EP2552943A2 (en) 2013-02-06
ES2461147T3 (es) 2014-05-16
AU2011231998A1 (en) 2012-10-25
US9803219B2 (en) 2017-10-31
DK2368903T3 (da) 2014-05-05
US20130089523A1 (en) 2013-04-11
EP2368903A1 (en) 2011-09-28
AU2011231998B2 (en) 2015-07-02
WO2011116974A2 (en) 2011-09-29
EP2552943B1 (en) 2018-05-09
EP2368903B1 (en) 2014-03-05
CA2794383A1 (en) 2011-09-29
WO2011116974A3 (en) 2012-01-05
US20170073704A9 (en) 2017-03-16
CA2794383C (en) 2015-12-01

Similar Documents

Publication Publication Date Title
US20240002882A1 (en) Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US9803219B2 (en) Adenovirus derived helper virus for enhancing recombinant parvovirus production
US7037713B2 (en) High-efficiency wild-type-free AAV helper functions
El-Andaloussi et al. Novel adenovirus-based helper system to support production of recombinant parvovirus
Cornelis et al. Vectors based on autonomous parvoviruses: novel tools to treat cancer?
Cornelis et al. Cancer gene therapy through autonomous parvovirus-mediated gene transfer
AU2012269386B2 (en) Oncolytic virotherapy for the therapy of sarcoma
Rommelaere et al. Autonomous parvoviruses
US9441246B2 (en) Adeno-parvovirus chimera with enhanced oncolytical potential
Vermeij et al. Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector
Smithwick Engineering and Optimization of an AAV Based Viral Vector to Limit the In-Vitro Expression of SARS-CoV-2 Spike-Protein
Smithwick Engineering and Optimization of an AAV6 Based Viral Vector to Limit the Expression of Sars-CoV-2 Spike-Protein
JP2024149508A (ja) 新規アデノ随伴ウイルス（ａａｖ）バリアント及び遺伝子治療のためのその使用
Cornelis et al. Helper-independent parvoviruses as gene therapy and vaccine delivery vectors